RE: Let me ask the stupid questions!23 Jun 2021 09:33
Morning BOJO
My initial thoughts were that it was to hive off one of the platforms and I wrongly feared that would be to our detriment.
However, having calmed down and been given explanations by Berm and GF it is correct to assume it is to allow for deals, licences or partnerships, possibly on this occasion solely for the Glycan Mabs platform.
It will be wholely owned subsidiary of Scancell Limited which intern is wholely owned by Scancell Holdings PLC, where our shares reside.
The science and IP owned by Scancell has so much potential value that this may be just the start of separating out the different elements making the process of out licencing and partnerships much less messy.
Chester.